^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
KA2507
i
Other names: KA 2507, KA2507
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Karus Therap, UT MD Anderson Cancer Center
Drug class:
HDAC6 inhibitor
Related drugs:
over4years
[VIRTUAL] Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors (AACR-I 2020)
Twenty pts with various tumor types commenced treatment from Aug 2017 to Aug 2019. The median age was 56 years (27-78 years) and 13 were males. The most common tumor types were adenoid cystic carcinoma (ACC, n=6) and colorectal cancer (n=4).
Clinical • P1 data
|
PD-L1 (Programmed death ligand 1)
|
KA2507
over4years
[VIRTUAL] A phase II study of selective HDAC6 inhibition with KA2507 for second-line treatment of advanced biliary tract cancer (ABC-11). (ASCO 2020)
Background: The ABC-02 trial provided Level A evidence supporting the use of cisplatin plus gemcitabine as first-line chemotherapy for advanced biliary tract cancer (ABC) [Valle, 2010]. In second line therapy oxaliplatin and 5FU and ivosedinib for IDH1 mutated cancers are options [Lamarca, 2019; Abou-Alfa, 2019] however there remains significant unmet need for patients without actionable alterations...The study received regulatory and ethical approval to proceed in January 2020 and enrolment is in progress. Research Funding: Karus Therapeutics Ltd
Clinical • P2 data
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
cisplatin • gemcitabine • oxaliplatin • fluorouracil topical • KA2507
Share via
